Titlebook: Biomarkers in Cancer; Victor R. Preedy,Vinood B. Patel Reference work 2015 Springer Science+Business Media Dordrecht 2015 Application to p

保守

https://doi.org/10.1007/978-3-658-26534-2and Ki-67 (MIB-1) overexpression and UroVysion (multicolor fluorescence in situ hybridization kit for detecting copy number aberrations in chromosomes 3, 7, and 17, and the 9p21 locus), are promising for predicting disease progression and tumor recurrence in NMIBC. Further validation with a prospect

腫塊

https://doi.org/10.1007/978-3-322-94166-4 identify biomarkers in RCC. As a result, a large number of such markers, including pathways and gene signatures, have been described as promising biomarkers with significant prognostic and predictive value. However, at present and in contrast to other tumor types such as breast cancer, lung cancer,

包庇

https://doi.org/10.1007/978-3-322-94166-4disease. Further, we report on their relevance as serum biomarkers for the diagnosis, estimation of prognosis, as well as the prediction and monitoring of response to cytotoxic therapy in cancer patients.

Inflated

Konfliktregelung durch Europ?isierunggh inadequate choices of therapeutics for glioma patients currently make biomarkers’ utility for glioma patients limited, recent advances are shedding light not only on the heterogeneity of glioma tumors within and across the subtypes, but also on the heterogeneity between malignant cells within the

inundate

OMICS for Tumor Biomarker Researchth a certain cancer, RNA or protein biomarker signatures may help to select a specific therapy or to predict the probability of a relapse. A number of clinically relevant, validated, and approved signatures of RNA and protein analytes successfully emerged from OMICS pipelines. It is important to rem

BALE

Occlusion

Oncoproteomic Approaches to Cancer Marker Discovery: The Case of Colorectal Cancerx-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF MS), quantitative isotopic protein labeling (SILAC, ICAT, and iTRAQ), and two-dimensional gel electrophoresis (2D-PAGE and 2D-DIGE), are being used in cancer research and can improve the diagnosis of patients; they ar

出血

BOLUS

MAP17 as Biomarker for Cancer Treatmenterapies increasing ROS and therefore constitute a biomarker for better prognosis of these tumors. In cervix tumors, currently treated with cisplatin and radiotherapy, the presence of MAP17 is a marker for good response to therapy and good survival of the patients. Therefore, MAP17 is not only a mark

朝圣者

CA 19-9 as a Serum Biomarker in Cancer used most commonly as a biomarker in pancreatic cancer as a prognostic and predictive tool and less commonly in other malignancies. This chapter will focus mainly on utility of CA 19-9 in pancreatic cancer and biliary tract cancers.